Report of Adverse Event Following Immunization (AEFI)

When completed, please send the form to your local <u>Public Health Unit</u> by a secure means. For more information about AEFI reporting in Ontario visit the <u>Public Health Ontario website</u>. **The form should be used to capture AEFIs for all vaccines, including COVID-19 vaccines.**

Case ID (for local use only):

Public	Santé
Health	publique
Ontario	Ontario

1 - CLIENT INFORMATION													
Client last name:						ŧ:	Date of Birth (yyyy/mm/dd):						
Quart													
Gender: Mal	e Female	Female Other Unknown Parent/guardian/caregiver full name, as applicable: Telephone #:											
Address:	Address: City: Postal Code:												
Reported to publi	ic health bv:			Relat	ionship with	case:			ם	ate of	report (yyy	v/mm/dd).	
	·				•							, ad).	
Form completed	by:			Conta	act informatio	on (if diffe	rent from above):						
2 - IMMUNIZATION INFORMATION													
						Lot #	Exp. date Dose # Site Route				Route		
(yyyy/mm/dd)	(24hr - HH:MM)		, igoni un					(yyyy/mm/dd)			2000 #	0110	liouto
Immunization e No l		es*		Previ	ous history a No Ui	nknown	Yes*		Vaccir	ie adr	ninistered	by:	
110 0		es escribe in S	Section 4				Describe in Secti	ion 4					
3 - ADVERSE EVENT INFORMATION (ALL VACCINES. FOR ADDITIONAL COVID-19 VACCINE SPECIFIC EVENTS SEE SECTION 4) Report only events which cannot be attributed to co-existing conditions. Reactions marked with an asterisk (*) must be diagnosed by a physician. Record the time to onset of the event (time between <u>vaccine administration</u> and <u>onset of each event</u>) and the duration of each event in minutes or hours or days. If the interval / duration is less than one hour record in minutes, if less than 24 hours record in hours, if greater than or equal to 24 hours record in days.													
	Specify minutes or hours or days Specify minutes or hours or days												
Local Reaction at the Injection Site Time to onset of event				ration of event	Allergic Reactions						ition of vent		
Pain/redness / swelling extending past nearest joint		g					ent managed as anap		Ļ			<u> </u>	
Pain/redness	/ swelling lasting					Oculorespiratory syndrome (ORS) Allergic reaction - skin (E.g. hives)							
4 days or mo							.	0	· L				
Sterile absces				+		Neurologic Events				ime to onset Duration of event			
Nodule				1		Co	nvulsions / seizure		1			1	
Cellulitis*						Encephalopathy / encephalitis*							
						Me	ningitis*						
Systemic React	ions		to onset event	Du	ration of event	An	aesthesia / paraesthe	sia*					
Fever greater	than 38.0°C					Pa	ralysis*						
(Only reportat with another e	ole in conjunction						ll's Palsy*		Ļ				
Rash				+		Guillian-Barré Syndrome (GBS)*							
	lymphadenopathy'					Myelitis / Transverse Myelitis*							
Hypotonic-hyperiate (HHE	ooresponsive			1			ute disseminated cephalomyelitis*						
	-) ing / screaming					Other	events of interest				e to onset f event		tion of vent
Severe vomiti (3 episodes/2						Th	rombocytopenia*		ľ				
(3 episodes/2	+ nours)						hritis / arthralgia		ŀ			1	
		L		1		l Inte	ussusception*		ľ			1	
						Ka	wasaki Disease*		ľ				

Syncope (fainting) with injury Other severe or unusual events

4 - COVID-19 ADVERSE EVENT(S) OF SPECIAL INTEREST

...

In addition to the adverse events listed on the page one, please indicate occurrence of any of the following reactions associated with administration of COVID-19 vaccine. These reactions should only be used for AEFIs reported following receipt of COVID-19 vaccine.

	Specify minutes	or nours or days	
COVID-19 AESI	Time to onset of event	Duration of event	COVID-19 AESI
Vaccine-associated enhanced disease			Acute kidney injury Acute liver injury
Multisystem inflammatory syndrome in children			Anosmia and / or ageusia
Acute respiratory distress syndrome			Chilblain like lesions Single organ cutaneous vasc
Acute cardiovascular injury			Erythema multiforme
Coagulation disorder			

;	Specify minutes or hours or days					
19 AESI	Time to onset of event	Duration of event				
e kidney injury						
e liver injury						
smia and / or ageusia						
lain like lesions						
le organ cutaneous vasculitis						
nema multiforme						

5 - COMMENTS FURTHER DESCRIBING THE ADVERSE EVENT(S)

Please provide a detailed description of the event including all signs and symptoms, medical history (e.g. immunocompromised, chronic illness/underlying medical conditions), concomitant medications, investigation, treatment, hospitalization details and description of previous history of AEFI or immunization error if indicated in Section 2.

6 - HEALTH CARE UTILIZATION & OUTCOME

Please provide information about health care utilization related to the event. Outcome to be updated by the Public Health unit when the investigation is complete.

					,		•		
Medical consultation (non-urgent)	Yes	No	Date (yyyy/mm/dd)		Name and address	of health professio	onal attending the event		
Seen in emergency department	Yes	No	Date (yyyy/mm/dd)		Name and address	e event was attended to			
Admitted to hospital because of event	Yes	No	Admission Date (yyyy/mm/dd)		Name and address of facility where the event was att (e.g., hospital name)				
			Discharge Date (yyyy/mm/dd)						
OUTCOME	Recovered		t yet recovered escribe below)	Permanent disa (describe below	bility / incapacity /)	Unknown	Death (describe below)		
Describe:	Date of outcome: (yyyy/mm/dd)					e:			
7 - MEDICAL OFF	7 - MEDICAL OFFICER OF HEALTH (MOH) RECOMMENDATIONS								
For Public Health Unit use	only. To be comp	leted by	the MOH or designate	э.					
Check all that apply:				MOH recommend	MOH recommendation comments:				
No recommenda	tion								
No change to immunization schedule									
Determine protective antibody levels (Specify)									
Active follow-up	nce afte	er next vaccine							
Controlled setting for next immunization			Medical Officer of Health (MOH) or Designate						
Expert referral (S	Expert referral (Specify)			Name: Date (yyyy/mm					
	No further immunization (Contraindication or series complete - Specify)			Signature:					
Other (Specify)									
The personal health information provided on this form is collected under the authority of the <i>Health Protection and Promotion Act</i> and O. Reg 569. The personal health information is used to signal adverse events that may require more in-depth investigation and to ensure the continued safety of vaccines on the Canadian market by monitoring adverse events following immunization with vaccines. The information collected may be shared with									

the Public Health Agency of Canada. If you have questions about the collection of this personal health information please contact your local public health unit.

Page 2/2 Updated December 2020

